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A B S T R A C T
Purpose
To evaluate the feasibility and safety of intratumoral injection of autologous dendritic cells
(DCs) transfected with an adenovirus encoding interleukin-12 genes (AFIL-12) for patients
with metastatic gastrointestinal carcinomas. Secondarily, we have evaluated biologic effects
and antitumoral activity.
Patients and Methods
Seventeen patients with metastatic pancreatic (n Z 3), colorectal (n Z 5), or primary liver
(n Z 9) malignancies entered the study. DCs were generated from CD14 monocytes
from leukapheresis, cultured and transfected with AFIL-12 before administration. Doses
from 10 106 to 50 106 cells were escalated in three cohorts of patients. Patients received
up to three doses at 21-day intervals.
Results
Fifteen(88%)and11of17(65%)patientswereassessablefor toxicityandresponse, respectively.
Intratumoral DC injectionsweremainly guided by ultrasound. Treatmentwaswell tolerated. The
most common side effects were lymphopenia, fever, andmalaise. Interferon gamma and inter-
leukin-6 serum concentrations were increased in 15 patients after each treatment, as well as
peripheral bloodnatural killer activity infivepatients.DCtransfectedwithAFIL-12stimulatedapo-
tent antibody response against adenoviral capsides. DC treatment induced amarked increase of
infiltrating CD8 T lymphocytes in three of 11 tumor biopsies analyzed. A partial response was
observed in one patientwith pancreatic carcinoma. Stable diseasewas observed in two patients
and progression in eight patients, with two of the cases fast-progressing during treatment.
Conclusion
Intratumoral injection of DC transfected with an adenovirus encoding interleukin-12 to pa-
tients with metastatic gastrointestinal malignancies is feasible and well tolerated. Further
studies are necessary to define and increase clinical efficacy.
J Clin Oncol 23:999-1010.  2005 by American Society of Clinical Oncology
INTRODUCTION
Surgical resection is the only curative treat-
ment available for gastrointestinal carcino-
mas. Unfortunately, a high proportion of
patients are diagnosed when current thera-
pies are largely ineffective.
Dendritic cells (DCs)1,2 are attractive
adjuvants for therapeutic immunization of
cancer patients.1,3 Immature DCs take up
and process antigens4,5 and, upon matura-
tion/activation, migrate to draining lymph
nodes where they can prime tumor-anti-
gen–specific CD4 and CD8 T cells.2,4,6
The DC maturation program includes:
downregulation of their capacity to acquire
antigens, increasedexpressionofmajorhisto-
compatibility complex and co-stimulatory
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molecules, changes in chemokine receptors,6,7 and enhanced
productionofkeycytokinessuchas interleukin(IL) -2, IL-12,
and IL-15.8-10Besides,matureDCshave the ability to activate
both natural killer (NK)11 and NK T cells.12
For immunotherapy, tumorantigensareprovided toDCs
in different forms such as incubating DCs with synthetic or
native peptides, tumor tissue lysates,13,14 purified proteins,15
tumor-derived total RNA,16 or by fusing malignant cells and
DCs.17 Furthermore, the efficacy of DC-based immunother-
apymayalso be increasedby transductionwith either cytokine
genes or co-stimulatory molecules (IL-2, IL-7, IL-12, second-
ary lymphoid-tissue chemokine, CD40-L) into DCs.18-24
IL-12 is a potent immunostimulatory cytokine, pro-
duced physiologically by DCs, which has shown properties
as an anticancer agent in experimental tumors, as a recombi-
nant protein,25 or in gene therapy approaches including de-
livery with transfected fibroblasts.26,27 Recently, we have
reported that intratumoral injectionofanadenovirusencod-
ing for human IL-12 (AFIL-12) to 21 patients with advanced
digestive malignancies was feasible and well tolerated.28 Up
to 3  1012 viral particles exert mild antitumor effect (one
partial response and six stable disease cases). Biologic effects
included increases in serum interferon gamma (IFN-) and
increases in the lymphocyte infiltrate in four of 10 patients.
We have previously demonstrated that repeated intra-
tumor injections of murine bone-marrow–derived DC
transfected with an adenovirus encoding IL-12 induce
a potent antitumoral response.21,29 Importantly, this strat-
egy not only eradicates the directly injected tumors, but
also distant disease demonstrating systemic immunity.29
The activity of CD8 T cells is crucial to achieve such
a therapeutic effect.21,22,30
We decided clinical translation of this strategy with in-
tratumoralmaturing/semimatureDCs,31 despite thepoten-
tial risk of inducing immunity to self antigens shared by
normal and cancer tissues.32 Both our preclinical data
and reports fromseveral phase I/II studieswere encouraging
and demonstrated the safety of immunotherapy with
DCs.3,33,34 Another potential drawback of this intratumoral
route of administration is the presence of immunosuppres-
sive factors at the tumor microenvironment that could en-
danger the performance of DCs even if transfected to
produce IL-12.35-37 Recent observations have highlighted
that under certain conditions tumor can exploit intratu-
moral DCs for their own growth.38 This article describes
the first clinical experience of intratumoral administration
ofDCs engineered to produce IL-12 by recombinant adeno-
virus, thus combining gene and cellular immunotherapy.
PATIENTS AND METHODS
Study Design
This was an open-label, nonrandomized, dose-escalation
phase I trial in which DCs transfected with AFIL-12 were admin-
istered intratumorally to patients with metastatic gastrointestinal
carcinomas.
Objectives. The primary end point was to assess both fea-
sibility and safety of direct intratumoral injections of DCs. Sec-
ondary end points were biologic effect and antitumor activity.
Patient Selection and Enrollment
Inclusion criteria included: (1) age $ 18 years; (2) metastatic
disease; (3) histologic diagnosis of primary liver cancer, colorectal
cancer, or pancreatic cancer; (4) an Eastern Cooperative Oncology
Group performance status # 3; and (5) an accessible tumor mass.
Exclusion criteria included: (1) pregnancy or lactation; (2) neutro-
phil count# 0.5 109/L or a platelet count# 20 109/L; (3) anti-
HIV antibodies; (4) an active infection; (5) contraindications for
leukapheresis; (6) active autoimmune disease; and (7) immuno-
suppressive treatment within the last 4 weeks before the first dose.
All patients provided signed informed consent. Permission was
granted by the institutional ethical committee, the local govern-
ment’s ethical committee, and the Spanish Agency for the Evalua-
tion of Medicinal Products.
AFIL-12 and Generation of Monocyte-Derived DCs
AFIL-12 was constructed and produced as described.28
Briefly, AFIL-12 is a first-generation, replication-defective adeno-
virus that encodes thehumanIL-12genesunder the transcriptional
control of a nonselective cytomegalovirus promoter. AFIL-12 was
expanded in293 cells, purifiedbycesiumchloridedensity gradient,
dialyzed, and stored at80°C. Clinical-grade AFIL-12with a viral
particle plaque-formingunits ratio of 12:65wasmanufactured and
certified by BioReliance (Glasgow, Scotland).
Isolation of PBMC and Clinical-Grade Purification of
CD141 Cells
Patients underwent a three-blood-volume leukapheresis
(Cobe Spectra; Gambro BCT, Lakewood, CO ). CD14 mono-
cytes were isolated using immunomagnetic beads (CliniMACS;
Miltenyi Biotec, Bergisch Gladbach, Germany). A fraction of
CD14 cells was slowly frozen to 120°C in autologous serum
with 10% volume/volume dimethylsulfoxide by using a cryo-
freezing container (CM-25, Carburos Meta´licos, Spain) for next
doses.
DC Cultures and Transfection
CD14 cells (106/mL) were cultured at 37°C and 5% CO2
in serum-free AIMV medium (GIBCO BRL, Grand Island, NY)
containing 1,000 U/mL of IL-4 (R&D Systems, Minneapolis,
MN) and 500 U/mL of granulocyte macrophage colony-stimulat-
ing factor (GM-CSF; Leucomax; Novartis, Basel, Switzerland).
Cultures were supplemented with cytokines at days 3 and 5.
On day 7, cells were washed with serum-free RPMI 1640
medium, counted, and resuspended at 5  106 cells/mL with
AFIL-12 at a multiplicity of infection (MOI) of 1,000 during 2
hours at 37°C. DCs were administered to patients 24 hours after
transfection. Previous experiments had documented that trans-
fection at MOI 1,000 with a similar adenovirus encoding the re-
porter gene -galactosidase routinely gave rise to 70% to 80%
-galatosidase cells. In the last four patients, the cells were ex-
posed 24 hours before administration to 50 ng/mL of tumor ne-
crosis factor alpha (TNF-; Boehringer, Ingelheim, Germany), 20
g/mL of prostaglandin E2 (Pharmacia, Uppsala, Sweden) and
1,000 U/mL of interferon alfa (IFN-; Schering-Plough, Dardilly,
France) to enhance maturation. Maturation was confirmed
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assessing increases in the immunofluorescence of CD80, CD86,
and human leukocyte antigen-DR (HLA-DR). Cell viability
was confirmed by the tripan blue exclusion test. Flow cytometric
analysis was performed at day 7 using FACScan (Becton Dickin-
son, San Diego, CA). Minimal quality criteria for DCs included
$ 75% HLA-DR and CD11cbright and negative microbial tests.
DC activity was confirmed in allogenic mixed lymphocyte reac-
tion cultures.
Treatment Plan
Patients were enrolled consecutively in three cohorts of five
patients each with the following dose-escalation plan: cohort 1:
107 DCs; cohort 2: 2.5  107 DCs; cohort 3: 5  107 DCs.
Two additional patients were included in the last cohort. Three
doses of DCs were administered intratumorally at 21-day inter-
vals. DCs were resuspended in saline and administered in one
single tumor location under ultrasound (US), computed tomog-
raphy (CT) scan or endoscopic US guidance.
Patient Evaluation
Figure 1 summarizes the evaluation of the patients throughout
the study. Appraisal before DC treatment also included Doppler
echocardiogram and bone scintigraphy. In-patients were carefully
monitored during the first 4 days after each treatment by daily eval-
uation of toxicity and a comprehensive set of hematologic and bio-
chemical laboratory tests at days 0, 1, and 3. On day 21, a tissue
sample was obtained from the injected lesion immediately before
the administrationof the seconddose.At day63, toxicitywas reeval-
uated and response to therapy was assessed using WHO criteria.39
Dose-limitingtoxicitywasdefinedasgrade4toxicityofanyduration
related toDCsornonreversible grade 3 toxicity related toDCs. Tox-
icity was assessed throughout the study using the National Cancer
Institute Common Toxicity Criteria.40 Relation to treatment of
adverse reactions observed were classified as definite, probable, or
possible according to Karch and Lasagna criteria.41
Immunologic Monitoring
Cytokine measurement. DCs (106/mL) were assayed for IL-
12p70production 24and48hours afterAFIL-12 infectionusing an
enzyme-linked immunoabsorbent assay (ELISA) kit in the culture
supernatant (Pharmingen, San Diego, CA). Simultaneous mea-
surement of IL-6, IL-10, TNF, and IL-12 in serum samples at
baseline and on days 0, 1, 2, and 3 after each dose of DCs from pa-
tientswas analyzedbymicroparticle-basedflow cytometry accord-
ing to manufacturer’s instructions (BD Bioscience, San Jose,
CA). IFN- levels were monitored by ELISA in serum samples
at baseline and on days 0, 1, 2, and 3 after each dose of DCs (Phar-
mingen).
NK activity. Cytotoxic NK activity against K562 cells was
measured by standard 5-hour sodium 51chromate-release assay as
described.30
Antiadenovirus antibodies measurement. Total and neu-
tralizing antibody titers against adenovirus were monitored by
ELISA and interference with infection by an adenovirus encoding
luciferase, respectively, at baseline and just before the second and
the third dose of DCs (manuscript in preparation).
Delayed-type hypersensitivity test. Delayed-type hypersen-
sitivity (DTH) skin tests were used to assess in vivo immune re-
action against autologous tumor antigens. Tumor tissue was
placed in phosphate-buffered saline and a single-cell suspension
was obtained. Cells were lysed by three to four freeze-and-thaw
cycles and debris was removed by centrifugation for 10 min at
2,000 rpm. Supernatants were collected, irradiated at 5,000
rads and aliquots stored at 80°C. GM-CSF 50 g were added
to each lysate solution. Skin tests were performed by 50 l intra-
dermal injection of this tumor lysate when indicated in Figure 1.
A solution containing AFIL-12 inactivated by ultraviolet light
were injected to assess reactivity against viral antigens.
Pathologic studies. Tumor samples obtained at baseline
and at day 21 were histopathologically analyzed as described.28
Surface area calculations were computer-assisted by image anal-
ysis software and positive cells were manually counted by a pa-
thologist blinded to the identity of the samples.
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Fig 1. Flow-chart of the clinical trial design. Treated tumors were biopsied at day 21. AFIL-12, adenovirus encoding interleukin-12 genes; DC, dendritic cells; DTH,
delayed-type hypersensitivity test; PBMC, peripheral blood mononuclear-cells; w, weeks.
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RESULTS
Patient Characteristics
Seventeen patients were enrolled between May 2002
and March 2004 (Table 1). Mean age was 56 years. Eight
patients had hepatocellular carcinoma (HCC), three had
pancreatic cancer (PC), five had colorectal cancer
(CRC), one had cholangiocarcinoma (ChC), and all of
them had metastatic disease. Six of the eight patients
with HCC had underlying liver cirrhosis due to hepatitis
C virus. All cirrhotic patients had portal hypertension
and a fairly preserved liver function (five cases of Child-
Pugh class A and one case of class B). Patients with PC
and CRC had had prior standard chemotherapy, whereas
most HCC patients received multimodal therapy includ-
ing surgery, transarterial embolization, or radiofrequency
ablation.
Generation of DCs
Results of leukapheresis. Autologous DCs were dif-
ferentiated in serum-free medium (AIM-V) from
CD14 monocytes. The immediate yield of thawed cells
alive was above 90% and ranged from 40% to 78%
(mean, 62%) after 24 hours back in culture.
The number of DCs injected was  75% of the
planned dose in all patients. After 8 days of culture, har-
vested cells were consistently 100% CD11c bright, being
nearly 50% CD1a, and expressed high levels of HLA-
DR (75%; Table 2) and intermediate levels of CD80 and
CD86 (41% and 44%, respectively). These findings were
Table 1. Patient Characteristics Before DC Administration (n Z 17)
Patient No. Sex/Age (years) Tumor Type ECOG PS Previous Therapy Site of Metastases
1 M/44 PC 0 RT/chemo L, P, LN
2 F/72 HCC* 0 TACE/surg/EI L
3 M/62 CRC 1 Surg/chemo/EI L, P
4 M/63 CRC 0 Surg/chemo L, Lu
5 M/72 HCC 0 PEI/TACE L, SC
6 M/21 HCC 2 Chemo L, Lu, LN
7 M/49 CRC 2 Surg/chemo/EI L, Lu
8 M/39 CRC 2 Surg/chemo L, B
9 F/55 PC 1 RT/chemo P, L, LN
10 M/73 HCC* 0 TACE L
11 M/56 CRC 0 Surg/chemo L, LN
12 M/49 PC 1 RT/chemo P, L, LN
13 M/69 HCC* 1 TACE/surg/EI† L, B, st
14 F/68 HCC* 1 Chemo L, B
15 F/73 HCC* 0 TACE L
16 M/39 HCC* 1 None L, LN
17 M/53 ChC 2 Chemo/RT L, B, LN
Abbreviations: DC, dendritic cell; ECOG PS, Eastern Cooperative Oncology Group performance status; PC, pancreatic cancer; RT, radiotherapy; chemo,
chemotherapy; L, liver; P, pancreas; LN, lymph nodes; HCC, hepatocellular carcinoma; TACE, trans-arterial chemoembolization; surg, surgery; EI,
experimental immunotherapy; CRC, colorectal carcinoma; Lu, lung; PEI, percutaneous ethanol injection; B, bones; st, soft tissue; ChC, cholangiocarcinoma.
*Concurrent chronic hepatitis C viral infection.
†EI including patients previously treated with adenovirus encoding interleukin-12 genes.
Table 2. Phenotypic Analysis of Cultured DCs (% positive)
Patient No. CD11c CD1a CD80 CD86 HLA-DR
1 99 57 33 49 50
2 100 40 24 97 95
3 100 49 23 58 54
4 94 87 27 9 90
5 100 36 54 94 98
6 100 25 33 48 83
7 100 78 37 16 96
8 100 16 23 46 88
9 100 82 35 23 41
10 100 63 68 48 70
11 100 66 68 36 43
12 100 67 26 27 65
13 99 31 36 17 80
14 99 40 10 18 79
15 100 40 72 65 64
16 100 29 88 88 85
17 100 88 46 14 94
Mean  SE 99.47  0.36 52.58  5.54 41.35  5.19 44.29  6.92 75  4.62
Abbreviations: DCs, dendritic cells; HLA-DR, human leukocyte antigen-DR.
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consistent with a phenotype of intermediate maturity or
‘‘in process of maturation/activation.’’31
Production of IL-12. In vitro transfected DCs with
AFIL-12 proved able to produce high amounts of IL-12
p70 at 24 and 48 hours (Table 3).
Treatment Procedure
Intratumoral injection of DCs was feasible in 100% of
cases. As shown in Table 4, 43 injections were adminis-
tered to the 17 patients guided by either US (n Z 38),
endoscopy US (n Z 3), or CT scan (n Z 2). Eleven pa-
tients underwent all of the three planned doses, with
four patients receiving two injections and two patients re-
ceiving only one injection.
Toxicity
A total of 118 adverse events were recorded through-
out the follow-up period (Table 5). In general, DC admin-
istration was well tolerated and dose-limiting toxicity was
not reached. None of the patients withdrew from the study
because of adverse events. Mild to moderate fever, respon-
sive to common antipyretics, was observed 24 to 48 hours
after DC injection in 65% of patients, irrespective of the
dose of DCs. Temperature increase was associated fre-
quently with malaise and occasionally with sweating.
Three patients experienced pain at the site of injection
that resolved in all cases with analgesics. Five patients
(29%) had grade 1 vomiting after the treatment. One pa-
tient experienced an episode of confusion in association
with a high dose of narcotic analgesics due to chronic
pain. Another patient developed progressive encephalop-
athy due to portosystemic shunt and died 40 days after the
first DC injection.
Six patients developed hypoalbuminemia after treat-
ment that could be associated with fluid therapy and
also to the concomitant cirrhosis. Grade 1/2 lymphopenia
was the most frequent adverse event, appearing in 14 pa-
tients (76%). Four grade 3 lymphopenia events were also
documented. Grade 1/2 lymphopenia before treatment
was common, but lymphocyte count almost invariably de-
creased at day 1 and returned to basal values by day 3. Mild
neutropenia was observed in three patients.
Table 3. In Vitro IL-12 Production by Dendritic Cells
IL-12 (ng/mL/106 cells) Mean  SE
Patient No. 24 Hours 48 Hours 24 Hours 48 Hours
1 7 39
2 400 530
3 14 160 98  41.45 212.2  50.2
4 1.2 37
5 68 295
6 25 68
7 0 164
8 0 0 10.8  3.16 117  30.35
9 25 313
10 4 40
11 2 3
12 2.09 3.3
13 3 10
14 4 8 7.41  0.91 21.47  1.67
15 11 20
16 8 52
17 22 54
NOTE. Supernatants from adenovirus IL-12 infected dendritic cells were
collected at 24 and 48 hours for quantification of IL-12 p70 by enzyme-
linked immunoabsorbent assay. Total IL-12 concentration in culture
supernatants are given.
Abbreviation: IL-12, interleukin-12.
Table 4. Summary of Dendritic Cell Administration
Dose (No. of DCs)
Treatment
Courses
Procedure of
Guidance
Clinical
Response*
10  106
Patient No.
1 3 US PR
2 3 US PD
3 3 US PD
4 3 US PD
5 3 US PD
25  106
Patient No.
6 2 US NA
7 2 US NA
8 1 US NA
9 3 EUS PD
10 3 US SD
50  106
Patient No.
11 3 US PD
12 2 CT NA
13 3 US PD
14 2 US NA
15 3 US SD
16 3 US PD
17 1 US NA
Abbreviations: DCs, dendritic cells; US, ultrasonography; PR, partial
response; PD, progressive disease; NA, not assessable; EUS, endo-
scopic US; SD, stable disease; CT, computed tomography.
*Tumor response was evaluated after the last treatment according to
WHO criteria.
Table 5. Adverse Events Possibly, Probably, or Definitely Related
to DC Treatment: Summary by Toxicity Grade
Grade
Event 1-2 3 4 Relation to DC
Lymphopenia 20 4 0 Definite
Fever 19 0 Definite
Sweating 3 0 Definite
Colostasis 4 0 Possible
Vomiting 6 0 Probable
Hyperbilirubinemia 5 0 Probable
Malaise 8 0 Definite
Leukopenia 5 0 Probable
Hypoalbuminemia 6 0 Possible
Anemia 4 0 Possible
Pain at site of injection 3 0 Probable
Neutropenia 3 0 Probable
Nausea 2 0 Probable
Vitiligo 1 0 Probable
NOTE. Adverse events observed between days 1 and 45 after
administration of dendritic cells. Adverse events were determined
using the National Cancer Institute Common Toxicity Criteria version
2.0. Relation to dendritic cell administration was classified as definite,
possible, or unlikely according to Karch and Lasagna.41
Abbreviation: DC, dendritic cell.
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No significant deterioration in hepatic function was
observed in cirrhotic patients (n Z 8). However, five pa-
tients (four with HCC) had a transient, mild hyperbiliru-
binemia shortly after treatment. Among patients receiving
multiple doses, side effects usually recurred, but cumula-
tive toxicity was not observed. In addition, there was no
clinical evidence of long-term toxicity among patients fol-
lowed for more than 6 months.
No clinical manifestations of autoimmune reactions
were observed with the exception of patient 5, who devel-
oped two small vitiligo lesions in the forehead after the third
dose of DCs. However, serum autoantibodies became de-
tectable or increased their titer in five cases (Table 6).
Biologic Response
Systemic production of cytokines. There was no sig-
nificant increase in serum IL-12 after treatment (not
shown). In contrast, serum IFN- increased after each
dose of DCs reaching the maximum level at day 1/2 after
treatment (Fig 2). IFN- concentrations appeared to be
dose dependent, ranging from 100 pg/mL in cohort 1 to
500 pg/mL in cohort 3. Although it is possible that released
IFN- could be the result of an unspecific immune re-
sponse against adenovirus, part of the IFN- detected sys-
temically could be the consequence of the expression of
IL-12 as a transgene, because DCs were injected when
they were producing high amounts of IL-12 (Table 3).
There was a great heterogeneity in the production of
Table 6. Titers of Antismooth Muscle Antibodies, Antinuclear Antibodies,
and Rheumatoid Factor Before Treatment and at Day 63
Titer
Autoantibodies Pretreatment Post-Treatment
Antismooth muscle antibodies
Patient No.
04 UD 1/80
09 UD 1/320
16 1/160 1/320
Antinuclear antibodies
Patient No.
11 1/80 1/640
16 UD 1/40
Rheumatoid factor
Patient No.
03 20 708
11 39 163
16 UD 45
Abbreviation: UD, undetectable.
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Fig 2. Increases in serum interferon gamma (IFN-) levels were detected in most patients after each DC dose (median). (A) Cohort 1; (B) cohort 2; (C) cohort 3.
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IL-12 in vitro by transfected DCs and, intriguingly, there
was no correlation between the amount of IL-12 produced
in vitro and the serum concentration of IFN-.
In addition, there was a dose dependent systemic pro-
duction of IL-6 in the majority of patients (Fig 3). It is well
known that IL-6 is produced in the context of an antiade-
novirus immune response, but IL-6 is also induced by IL-
12 and could contribute to enhance immune responses.42
NK-cell activity. Before DC administration, NK ac-
tivity was low or undetectable (Fig 4). Five patients devel-
oped increases of peripheral blood NK activity after
treatment. Among patients who showed increased NK ac-
tivity, one patient achieved a partial response and another
patient experienced a clear stabilization of her disease (pa-
tient No. 15).
Antiadenovirus antibodies. To explore the possibility
that DCs infected with an adenovirus encoding IL-12 gene
may immunize against viral antigens, we measured anti-
bodies against adenovirus. All patients had high pre-
existing levels of total and neutralizing antiadenovirus
antibodies (Fig 5). The great majority of patients increased
the titer of antibodies against adenovirus after DC injection
in a dose-dependent fashion. It should be noted that DCs
were extensively washed before injection and, accordingly,
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Fig 3. Serum interleukin-6 (IL-6)
levels induced after each treatment.
(A) Cohort 1; (B) cohort 2; (C) cohort 3.
Pt, patient.
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only internalized or strongly DC-absorbed viral particles
should have remained in the injected doses. These results
suggest an adjuvant activity of DCs for boosting antibody
production.
DTH tests. DTH skin test reactivity towards tumor
extracts were negative in 13 patients assessed, the only
exception being a weak positive reaction in patient No. 10
that declined 1 week later. However, the reaction against
inactivated AFIL-12 was positive in all patients after
therapy.
Pathologic study. A tumor sample was obtained at
day 21 in all but three patients. The quality of samples per-
mitted comparison of the two specimens in 11 patients. In
five of these cases (patients 10, 11, 13, 15, and 16; all of
them had HCC), there was a substantial augmentation
of the tumor infiltration by lymphocytes, with increases
in CD3 and CD8 cells ranging from 51% to 344% and
from 28% to 325%, respectively (Fig 6A). Importantly,
patients 10 and 15 experienced stabilization of their met-
astatic disease. As an example, Figure 6B shows immuno-
histochemical staining for CD8 lymphocytes in tumor
tissue sections from patient 10. In the remaining six pa-
tients, there were no significant changes in the level of lym-
phocyte infiltration (not shown).
Antitumor Response
Response to therapy was evaluated at day 63 in 11 of
17 patients. Two patients with CRC, patients 7 and 8,
withdrew from the study due to rapid progression of their
liver metastases before receiving second and third dose of
DCs, respectively. One patient with PC (patient 12) devel-
oped peritoneal carcinomatosis and tense ascitis and was
excluded from the study shortly after the second dose of
DCs. Another patient with metastatic ChC died prema-
turely after a sudden development of a Budd-Chiari syn-
drome and liver failure due to an aggressive procoagulant
state. Patient 6 was not evaluated because he died before
the administration of the third dose of DC due to enceph-
alopathy and noninfectious refractory fever. Hence, only
Pretreatment Posttreatment
Ly
si
s 
(%
)
Pt 01 Pt 02 Pt 08 Pt 15 Pt 16
PR SDPD PD PD
0
5
10
15
20
25
30
35
Fig 4. Natural killer (NK) -cell activity. NK-cell activity against K562 of
peripheral bloodmononuclear-cells of indicated patients, as evaluated before
and after dendritic cell treatment (effector/target ratio:100). PR, partial
response; PD, progressive disease; SD, stable disease; Pt, patient.
Cohort 1
B
1
10
100
1,000
10,000
100,000
1,000,000
Pt 01 Pt 02 Pt 03 Pt 04 Pt 05
Cohort 2
1
10
100
1,000
10,000
100,000
1,000,000
Pt 06 Pt 07 Pt 08 Pt 09 Pt 10
Cohort 3
Pt 11 Pt 12 Pt 13 Pt 14 Pt 16Pt 15
Cohort 1
Basal
Before second dose
Before third dose
Basal
Before second dose
Before third dose
ND
ND NDND
ND
A
1
10
100
1,000
10,000
100,000
1,000,000
Pt 01 Pt 02 Pt 03 Pt 04 Pt 05
Cohort 2
T
o
ta
l A
n
ti
b
o
d
ie
s
1
10
100
1,000
10,000
100,000
1,000,000
Pt 06 Pt 07 Pt 08 Pt 09 Pt 10
Cohort 3
T
o
ta
l A
n
ti
b
o
d
ie
s
1
10
100
1,000
10,000
100,000
10,000,000
Pt 11 Pt 12 Pt 13 Pt 14 Pt 16Pt 15
1,000,000
T
o
ta
l A
n
ti
b
o
d
ie
s
Ne
ut
ra
liz
in
g 
An
tib
od
ie
s
Ne
ut
ra
liz
in
g 
An
tib
od
ie
s
Ne
ut
ra
liz
in
g 
An
tib
od
ie
s
1
10
100
1,000
10,000
100,000
10,000,000
1,000,000
Fig 5. Antiadenovirus antibodies. All patients demonstrated a rise in antibody titers in response to dendritic cell treatment. (A) Total antibodies; (B) neutralizing
antibodies. ND, not done; Pt, patient.
Mazzolini et al
1006 JOURNAL OF CLINICAL ONCOLOGY
159.237.12.82
Information downloaded from jco.ascopubs.org and provided by at Universidad de Navarra on July 4, 2011 from
Copyright © 2005 American Society of Clinical Oncology. All rights reserved.
11 patients received complete treatment and were assessed
for antitumoral response. Two patients with metastatic
HCC showed stable disease and eight patients showed
tumor progression. A partial response was observed in
patient 1, who had metastatic PC that had progressed
even after radiochemotherapy. He received three doses
of 10 106 DCs into primary tumor mass and a reduction
in the number of noninjected liver metastases was ob-
tained. Importantly, the response persisted more than 3
months. Figure 7 shows abdominal CT scans from this pa-
tient taken before and after three injections of DCs. Remis-
sion lasted 3 months but duodenal obstruction due to
primary tumor progression developed at that time.
Patient 4 with CRC showed a significant decrease in
serum levels of carcinoembryonic antigen without CT
scan evidence of response or stabilization. In contrast,
DC treatment was followed by an increase of carcinoem-
bryonic antigen in patients 7 and 8 with progression of
their liver metastases from CRC.
DISCUSSION
In this study we demonstrate for the first time that intra-
tumoral administration of DCs engineered to produce IL-
12 by recombinant adenovirus is both feasible and safe in
humans.
We, and others, have previously shown that intratu-
moral injection of bone marrow–derived dendritic cells
engineered to produce IL-12 by means of viral vectors21,22
induces a potent immune response in mice. In these ani-
mals, neither toxicity nor any sign of autoimmunity were
ever found.21,22,29
We have recently finished a phase I study in which pa-
tients with advanced digestive carcinomas safely received
direct intratumoral injections of AFIL-12.28 Hence, this
previous study provided us with key information about
the safety of the viral vector at much higher doses than
those used to transfect DC.28
Clinical trials with DCs loaded with peptide or tumor
lysate, that include experience with gastrointestinal
carcinomas, show increases in T-cell–mediated specific
immunity against the tumor antigens used in these
vaccines.14,34,43-46 The intratumoral route of administra-
tion sounds attractive because T-cell–defined tumor anti-
gens have been identified for only a minority of human
cancers47 and because in certain tumors, such as digestive
tumors, it is difficult to obtain sufficient malignant cells as
a source of antigen. The idea of injecting DCs intratumor-
ally pursues artificial tumor antigen cross-priming,4,5 re-
sembling physiologic antigen presentation.6 However,
exposure of DCs to the suppressive local environment
might be a serious pitfall. In fact, local effects of transform-
ing growth factor beta, vascular endothelial growth factor,
IL-10, and prostaglandins on injected DCs might seriously
damage their functional capabilities.35,36,48 Nonetheless,
results obtained in mice strongly suggest that intratumoral
administrations might be more efficacious than all the in-
travenous and subcutaneous routes when tested in paral-
lel.49,50 Unfortunately, those studies did not include direct
comparisons with intranodal release of DCs, as it is being
performed in various clinical trials.14,31,34
Despite the purity of magnetic bead–selected mono-
cytes, the resulting phenotype of DCs after 7 days of culture
in thepresenceof IL-4andGM-CSFwasheterogeneouswith
regard to CD1a and other surface markers, indicating indi-
vidual variability in the differentiation culture frommono-
cytes even in defined serum-free medium. Moreover, there
was a remarkable heterogeneity in the production of IL-12
after transfection with AFIL-12. This could be explained by
an individual susceptibility of DCs to adenoviral transduc-
tion that can be genetically determined.51
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Adenovirus transfection is known to elicit partial mat-
uration of DCs,52,53 but we sought to further push the
maturation program of the DCs with the TNF-, prosta-
glandin E2, and IFN- cocktail in the last three patients.
SuchmaturedDCs had a profile of safety and biologic activ-
ity comparable to those that did not undergo this matura-
tion culture, without any remarkable clinical difference.
DC doses elicited systemic production of IFN- in
a dose-dependent manner. Serum IFN- was not clearly
correlated, with neither clinical response nor with toxicity.
Serum concentrations of IL-6 had a comparable response
pattern. However, IL-6 can be suppressive of IFN- func-
tions by inducing suppressor of cytokine signaling-154 and
signal transducer and activator of transcription-3. Hence,
it remains to be seen whether IL-6 triggered by our treat-
ment is beneficial or pernicious. Five of 15 patients devel-
oped increases of NK activity in peripheral blood after
treatment that could be related to well-described effects
of IL-12 on NK cells, as well as to DCs’ cross talk with NK
cells.11,30 A recent report shows the critical role of IL-12
in the activation of NK cells through membrane contact.55
Among the cases experiencing this transient increase of
NK activity, one patient underwent a partial response and
another patient had stabilization of her disease. Moreover,
we have observed an increment in NK activity in patients 1,
2, 8, and 15, who experienced high concentrations of
IFN- after treatment suggesting a potential correlation
between both phenomena. Therefore, either direct cytotox-
icity or proinflammatory functions of NK cells might be
involved in beneficial effects of the treatment.
We found a substantial increase in the amount of both
CD3 and CD8 T lymphocytes infiltrating the tumor in
four of 11 patients after a single dose of DCs. Although two
of these patients experienced stabilization of their tumor le-
sions, further studies will address whether infiltrating lym-
phocytes were specific for any tumor antigen and whether
they are endowed with cytolytic effector machinery.
A comparison of these biologic effects with those ob-
served upon intratumoral injection of AFIL-12 indicate
that there is an additional effect mediated by DCs, at least
in terms of IFN- secretion and NK cell activation.55
Evaluation of the T-cell immunity against tumors was
an extremely difficult task due to the limited access to
biopsy antigenic material. In two cases, there are data
showing increased ELISPOT reactivity to tumor lysate.
However, the limited amount of this tumor material pre-
cludes repetition and extension of these observations to
a sufficient number of patients as to draw firm conclu-
sions. On the contrary, reactivity to adenoviral capsides
was evident in all eight studied cases both by DTH and
by IFN- ELISPOT (not shown).
Patients increased antibody titers against adenovirus,
most of which were able to neutralize infection by this viral
vector. This fact further supports experiments in rodents
suggesting that DCs carrying absorbed viral particles act
as adjuvant for antibody responses.56 Inour case, adenoviral
transfected DCs carry much less viral particles than those
used in the previous trial and, by contrast, the increases
in antibody titer are higher, indicating adjuvant activity
of DCs.
Our studies offer solid ground to support that intra-
tumoral injection of up to 5  107 DCs in patients with
metastatic disease, including patients with advanced cir-
rhosis, is safe. Of note, one patient developed mild vitiligo
that was not associated with any other sign of autoimmu-
nity or any rise in the titer of autoantibodies. In this
regard, increments in the titer of antismooth muscle
antibodies, antinuclear antibodies, or rheumatoid factor
A B
Fig 7. Clinical response to dendritic cell (DC) treatment. Computed tomography scans of patient 1 with metastatic pancreatic carcinoma who showed partial
regression of liver metastases after the third dose of DCs injected into the primary tumor (A) before treatment and (B) after treatment.
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were observed in five patients, but no clinical signs of au-
toimmunity have been recorded, as it has been the case in
other DC-based protocols.3
The preliminary appraisal of clinical efficacy included
one partial response and two cases of stable disease. If
compared with the previous clinical trial using intratu-
moral AFIL-12, the clinical results were comparable, al-
though more cases showed tumor stabilizations in the
previous one. However, the second study recruited pa-
tients with more advanced and metastatic disease. Two
lines of research can be fruitful to improve these effects:
(1) introducing changes to fight the immunosupressive tu-
mor microenvironment, such as local radiotherapy57 or
molecular interference with DC-suppressing factors
(TGF-, IL-8, vascular endothelial growth factor); and
(2) to further enhance the elicited immune response
with cytokines58 or immunostimulating monoclonal anti-
bodies.29,59,60 Better clinical results would probably be
seen in patients with resectable tumors and microscopic
residual disease at high risk of recurrence.
- - -
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